Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

NCT00228163 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00228163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00228163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2002
Completion date
January 31, 2015
Enrollment
147 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis